Boards & Committees - Board of Directors
BOARD OF DIRECTORS
BOARD MEMBERSJob Description for the ISHLT Board of Directors
(Parentheses after name indicates year rotating off Board)EXECUTIVE OFFICERS:
Newcastle Upon Tyne, UKAndrew Fisher is Academic Director and Honorary Consultant Respiratory and Transplant Physician at the Institute of Transplantation, Freeman Hospital, Newcastle Upon Tyne and Professor of Respiratory Transplant Medicine at Newcastle University Medical School. He graduated from Nottingham University in 1993 and received research training as an Medical Research Council training fellow in Newcastle and Edinburgh 1996-99. He was subsequently awarded a GlaxoSmithKline Senior Clinical Research Fellowship 2005-2010. He has previously served as Chair of the British Thoracic Society Science and Research Committee 2009-2012 and Chair of the European Respiratory Society Lung Transplant Group 2010-2013.
Stanford University School of Medicine
Stanford, CA, USAJeffrey Teuteberg, MD, is an Assistant Professor of Medicine and Section Chief of Heart Failure, Cardiac Transplantation and Mechanical Circulatory Support at Stanford University. He joined the Stanford faculty in July 2017 after spending the prior 12 years at the University of Pittsburgh Medical Center. He specializes in the care of patients with advanced cardiomyopathies, cardiac transplantation, and ventricular assist devices.. He has particular interests in advanced heart failure and the transition to cardiac transplantation and ventricular assist devices. Dr. Teuteberg graduated from the University of Chicago, Pritzker School of Medicine, in 1992 and remained at the University of Chicago for his Internal Medicine Residency and general Cardiovascular Fellowship, during which he spent a year as the Chief Medical Resident. Dr. Teuteberg received his Heart Failure and Cardiac Transplant training at Brigham and Women's hospital in Boston.
University of Wisconsin
Madison, WI, USAMaryl R. Johnson, MD, is the Medical Director of Heart Failure and Transplantation and Professor of Medicine at the University of Wisconsin in Madison. She received her medical degree from the University of Iowa College of Medicine where she also completed postgraduate training in Internal Medicine and Cardiovascular Diseases. She joined the faculty at Iowa and was instrumental in the establishment of a cardiac transplant program, serving as the Medical Director of Cardiac Transplantation from 1984-1988. Her subsequent career has been entirely devoted to the care of patients with heart failure and following cardiac transplantation. Dr. Johnson's clinical interests are in the care of patients with severe congestive heart failure, including the use of mechanical circulatory support devices and cardiac transplantation. She has a particular interest in the treatment and outcome of congestive heart failure in women. Her research interests include the use of mechanical assistance in patients with severe heart failure and the coronary artery disease which develops in cardiac transplant recipients. She has also been an investigator in many of the multicenter trials evaluating new agents for the medical treatment of heart failure.
Duke University Medical Center
Durham, NC, USAJoseph Rogers is a Professor of Medicine at Duke University who specializes in adult cardiology, heart failure, heart transplant and mechanically assisted circulation. He obtained his medical degree from the University of Nebraska where he also performed his medical residency. He completed research and clinical cardiology training at Washington University in St. Louis prior to accepting a position as an attending cardiologist at Washington University and Barnes-Jewish Hospital. During his 10-year career at Washington University, he was the medical director of the cardiac transplant program. In 2004, he joined the faculty at Duke University and directed the cardiac transplant and mechanical circulatory support programs. His primary research interests include clinical trials in mechanically circulatory support and advanced heart failure.
Children's Hospital Medical Center
Cincinnati, OH, USALara Danziger-Isakov, MD, MPH, practices pediatric infectious diseases at Cincinnati Children's Hospital Medical Center where she is the Director of Pediatric Immunocompromised Host Infectious Diseases and Professor of Pediatrics at the University of Cincinnati. Dr. Danziger-Isakov earned her MD at Case Western Reserve University School of Medicine and complete her residency in Pediatrics at the Cleveland Clinic. She also completed a fellowship in Pediatric Infectious Diseases at St. Louis Children's Hospital and Washington University. Dr. Danziger-Isakov is board-certified in Pediatrics and Pediatric Infectious Diseases by the American Board of Pediatrics. Her clinical interests include pediatric infectious diseases, infections in transplant recipients, and infections in immunocompromised patients. Her research interests include outcomes related to infection after pediatric transplantation with an emphasis on pediatric and adult lung transplantation. In addition, Dr. Danziger-Isakov participates in clinical trials to evaluate new infectious disease therapies, new methods of detection for infectious diseases, and vaccination in immunocompromised hosts.DIRECTORS:
University of Michigan Health System
Ann Arbor, MI, USAKevin M. Chan, MD, is Professor of Medicine and Medical Director of the Lung Transplant program at the University of Michigan in Ann Arbor, MI, USA. He has been involved with lung transplantation since his fellowship training at the University of California Los Angeles and has also been associate director or director of lung transplantation at the University of Southern California and Henry Ford Hospital in Detroit. Dr. Chan’s primary research focus has been on post-transplant infections, improving patient outcomes and more recently, organ allocation policy development. He has been involved with the United Network for Organ Sharing (UNOS)/Organ Procurement and Transplant Network (OPTN) in various volunteer capacities over the years. Dr. Chan is the Fellowship Director for Pulmonary and Critical Care Medicine at the University of Michigan and has been a previous Scientific Program Chair as well as a leader in other professional organizations. He brings his expertise in clinical lung transplantation, policy development, organizational understanding and medical education to the ISHLT.
University of Pennsylvania
Philadelphia, PA, USAJason D. Christie, M.D., M.S. is the Chief of the Pulmonary, Allergy, and Critical Care Division. He is Professor of Medicine in the Department of Medicine and Professor of Epidemiology in the Department of Biostatistics and Epidemiology at the University of Pennsylvania. He is a Senior Scholar in the Center for Clinical Epidemiology and Biostatistics. His career is focused on translational research studies of the risks, pathogenesis, treatment, and outcomes of acute lung injury (ALI) in the transplant and non-transplant human populations. Through leadership of the Center for Translational Lung Biology, Dr. Christie brings together clinicians, bench scientists, epidemiologists, and statisticians to build multidisciplinary research teams. His research integrates new knowledge generated from bench studies with epidemiology approaches in well-phenotyped, large human populations to generate new definitions of human syndromes, improved diagnostics and prognostics, and targeted therapy approaches in advanced lung diseases and critical illness.
Henry Ford Hospitals
Detroit, MI, USADr. Jennifer Cowger is the medical director of the Henry Ford Mechanical Circulatory Support Program in Detroit, Michigan. She has a masters in biostatistics & clinical trial design from the University of Michigan and is the chair of the IMACS research committee and is on the DAAP Committee of INTERMACS. She joined the ISHLT board of directors in 2017 and is a liaison for the Education committee.
University of California, San Francisco
San Francisco, California, USATeresa De Marco, MD , completed her internal medicine residency and cardiology fellowship at the University of California, San Francisco (UCSF). She completed training in heart transplantation at the University of Utah Medical Center in 1989 and since then has been on the faculty at UCSF. She is Board Certified in Internal Medicine, Cardiovascular Medicine and Advanced Heart Failure/Transplant Cardiology. She is currently Professor of Medicine and Surgery. She holds the R.H. and Jane G. Logan Endowed Chair in Cardiology. She is the Director of the Advanced Heart Failure Therapies Program and Medical Director of Heart Transplantation. She is Director of the Adult Pulmonary Hypertension Comprehensive Care Center. She serves as Director of the Advanced Heart Failure and Transplant Cardiology Fellowship Program.
University of California - San Francisco
San Francisco, CA, USATobias Deuse is Transplant and MCS Surgeon at the University of California San Francisco. He completed his cardiothoracic residency in Munich and Hamburg, and completed a fellowship in Thoracic Transplantation and Mechanical Circulatory Support at Stanford University. His main clinical interests are minimally-invasive lung transplantation and minimally-invasive LVAD implantation. His research focus includes the development of new immunosuppressive/ immunomodulatory agents and alternative forms of administration like inhaled immunosuppression or cell-based immunomodulation. He is also active in the field of pluripotent stem cell research and tissue regeneration.
Drexel University College of Medicine
Philadelphia, PA, USAHoward J. Eisen, MD received his MD from the University of Pennsylvania School of Medicine in 1981. He did his Internal Medicine residency at the Hospital of the University of Pennsylvania and his Cardiovascular Fellowship at Washington University in St. Louis/Barnes Hospital and completed this training in 1987. In 2005, Dr. Eisen was appointed Thomas J. Vischer Professor of Medicine and Chief of the Division of Cardiology at the Drexel University College of Medicine and Hahnemann University Hospital. He subsequently also was installed as the Joseph DiPalma MD Famaily Professor of Cardiology. Dr. Eisen has led several clinical trials in cardiac transplant recipients including the everolimus clinical trials and has been involved in the development of gene expression profiling in cardiac transplant patients. He has chaired AHA research study sections and has been a member of NIH study sections. Dr. Eisen’s research has been funded by the American Heart Association of which he was an Established Investigator, the NIH and industry.
Heart and Diabetes Center NRW
Bad Oeynhausen, GERMANYStephan Ensminger, M.D., D.Phil. is a Professor of Cardiothoracic Surgery and one of the Deputy Heads of the Department of Thoracic and Cardiovascular Surgery at the Heart and Diabetes Center NRW, Ruhr University Bochum at Bad Oeynhausen, Germany. Dr. Ensminger graduated from the University of Würzburg Medical School in 1996, followed by an internship in Cardiothoracic Surgery at the University of Tübingen, Germany and a D.Phil. in Transplantation Immunology at the Nuffield Department of Surgery at the University of Oxford, U.K. under the supervision of Prof. Kathryn Wood in 2000. He received his cardiothoracic surgery training at the University of Erlangen-Nürnberg, Germany, where he was appointed as a Professor of Experimental Cardiac Surgery in 2008. His particular interests are Transplantation Immunology with the main focus on the immunobiology of cardiac allograft vasculopathy (CAV) and minimally invasive cardiac surgery with the emphasis on catheter based valve therapies (TAVR). He is currently a member of the executive board of the German Society of Thoracic and Cardiovascular Surgery and the German Aortic Valve Registry (GARY).
Montefiore Medical Center
Bronx, New York, USADr. Daniel J. Goldstein is a Professor at the Albert Einstein College of Medicine and Vice Chairman of the Department of Cardiothoracic Surgery at Montefiore Medical Center in New York where he also serves as the Director of the Mechanical Assistance Program. He is a graduate of the Mount Sinai School of Medicine (1991) and completed his general surgery and cardiothoracic surgery training at Columbia Presbyterian Medical Center in New York in 2000. While clinically active in all aspects of adult cardiothoracic surgery including coronary, valvular and aneurysmal heart disease, his clinical and research interests focus on the surgical management of end stage heart disease including stem cell therapies and pharmacological adjuncts for induction of left ventricular recovery in patients supported with left ventricular assist devices. Dr. Goldstein is an active member of the INTERMACS adverse event committee and has partaken as principal site investigator in multiple industry-based and NIH-supported clinical ventricular assist device trials.
The Prince Charles Hospital
Brisbane, AUSTRALIADr Peter Hopkins is the Director of the Queensland Lung Transplant Service and Associate Professor with the School of Medicine, University of Queensland, Brisbane. Research interests include First in Man clinical trials of innovative bronchoscopic techniques of lung volume reduction and development of novel treatment strategies for interstitial lung disease. Executive positions are held with the Australian Lung Foundation (PIVOT and the Australian IPF Registry), Deputy Chair of the Lung Standing Committee Transplant Society of Australia and New Zealand, Convenor SIG Interventional Bronchoscopy Thoracic Society of Australia and New Zealand and National Examiners Panel Royal Australian College of Physicians.
University of Minnesota Medical Center
Minneapolis, MN, USADr. Michael Petty is the Cardiothoracic Clinical Nurse Specialist at the University of Minnesota Medical Center, Minneapolis, MN. He received his initial nursing degree from St. Mary’s Junior College, Minneapolis, MN, and subsequently obtained a Bachelors Degree in Nursing from the University of the State of New York, and a Masters Degree and PhD in Nursing from the University of Minnesota. He began his career as a staff nurse in the Surgical ICU at the University of Minnesota Hospital and Clinic, and has held a variety of clinical, administrative, and industry roles in the subsequent years. Much of his focus and interest during that time has been in the care of patients with cardiovascular disorders requiring medical, surgical, and transplant interventions. He has been an active participant in the Mechanical Circulatory Support community since 1995 including serving as president of the International Consortium of Circulatory Assist Clinicians (ICCAC) in 2013. His clinical research interests focus on thoracic transplant and family caregivers of MCS patients.
University Hospital Gasthuisberg
Leuven, BelgiumDirk Van Raemdonck, MD, PHD, is a Professor of Surgery at the Katholieke Universiteit Leuven and Chair of the Leuven University Hospitals Transplant Center, Leuven, Belgium. As a General Thoracic Surgeon he currently serves as the Surgical Director of the Leuven Lung Transplant Program. He graduated as MD from the Katholieke Universiteit Leuven in 1984. He finished his training in general surgery in 1990 and in thoracic surgery in 1992. He was a registrar in thoracic surgery at the East Birmingham Hospital, Birmingham, U.K in 1990 (Prof HR Matthews), research fellow at the Memorial Sloan-Kettering Cancer Center, New York, N.Y. in 1991 (Dr RJ Ginsberg), and cardiothoracic transplant fellow at the Freeman Hospital, Newcastle-upon-Tyne, U.K. in 1991 (Prof JH Dark). He obtained his PHD degree from the Katholieke Universiteit Leuven in 1998. His main research topic is lung transplantation with particular interest in primary graft dysfunction, donation from donors after circulatory death, and ex-vivo lung perfusion. He is a current Board member A of Eurotransplant International Foundation since 2005 and previously served as the President of the European Society of Thoracic Surgeons (2012-2013) and as chair of the Thoracic Committee within the European Society for Organ Transplantation (2006-2012).EX-OFFICIO BOARD MEMBERS:
Addison, Texas, USA
Approved October 20, 2017
The Board of Directors is made up of the five ISHLT officers (the President-elect, President and Past-President, who serve 1 year terms in each office, and the Secretary and the Treasurer who each serve 1 year terms) and at least 11 and not more than 16 Directors who each serve 3 year terms. The Executive Director serves as an ex officio, non-voting member of the Board. Each Board member is assigned by the President to serve as the Board Liaison to one or more Councils or Committees.
- Manage the affairs, property, business, and all legal matters of the Society
- Provide appropriate and effective governance and leadership of ISHLT
- Update as needed and carry out the Society’s established mission and purposes
- Engage in strategic thinking and planning to develop and update as needed a strategic framework for the Society’s future
- Develop, measure progress on, and regularly update clear and defined goals, objectives, tactics, programs, and services for implementing the strategic framework
- Establish the organization’s values
- Make decisions on behalf of the Society as a whole in accordance with its mission, purposes, values, and strategic framework
- Provide the volunteer and financial resources necessary to accomplish ISHLT’s goals, objectives, programs, and services
- Approve an annual budget
- Provide prudent financial oversight of the Society
- Set goals and priorities for and approve an annual plan of work for programs and services of the Committees / Councils / Workforces / Board no later than October 31 of each year
- Provide timely and effective oversight of and guidance to ISHLT's volunteer leaders and the Executive Director
- Fully support and adhere to the processes, procedures, deadlines, and operations established by Staff to fulfill the Scope of Services
- Appoint standing and special committees
- Develop policies regarding leadership designation and governance of the committees
- Determine the purpose, number, and specific designations of the Scientific Councils, based on the scientific interests and constituencies of the members
- Develop policies regarding leadership designation and governance of Scientific Councils
- Develop and maintain corporate policies to address Society programs, services, and operations, including but not limited to internal financial policies, employment policies, investment policies, a whistleblower policy, and a document retention policy
- Contract for management services, negotiate and agree upon expectations and deliverables, and assess performance in accordance with agreed upon expectations and deliverables
- Define clear deliverables, expectations, deadlines, and performance metrics for the goals, objectives, programs, and services
- Ensure that volunteers and the ED understand the deliverables, expectations, deadlines, and performance metrics for the goals, objectives, programs, and services
- Provide regular and informed oversight of the work of volunteers and progress toward goals
- Decide on the path forward for projects that may not be progressing appropriately and provide feedback/course correction
- Hold volunteer leaders accountable for timelines, deliverables, and compliance with ISHLT policies, procedures, and expectations
- Regularly evaluate the performance of and provide feedback to the Board as a whole, the individual Board members, and all other volunteer leaders
- Establish a culture of transparency, honesty, and respect among Board members, Volunteer leaders, the ISHLT membership, and staff
- Ensure a process is in place for handling management company and Executive Director succession planning and unscheduled departure
- Assure adherence to Society Bylaws and legal requirements
- Approve new policies and changes to existing policies in a timely manner
- Identify, address, and resolve conflicting opinions / priorities of members
- Attend and participate in all in-person Board meetings and conference calls
- Prepare for Board meetings and conference calls by fully reviewing agenda and supporting materials, asking informed questions, making value-added contributions to the discussions, and making decisions based on the best interests of the Society as a whole
- Respond promptly and by the deadline to all assigned tasks
- Treat Board members, staff, volunteers, and members with respect
- Attend and actively participate in Board orientation and leadership development sessions
- Actively participate in the development and prioritization of goals, objectives, and tactics intended to further the strategic plan
- Actively participate in Board self-assessment and other volunteer assessment activities as requested
- Understand and adhere to all conflict of interest policies of the Society
- Represent ISHLT’s best interests, promote the ISHLT brand, and serve as an ambassador for the Society
- Refrain from communicating to others on behalf of the Board unless given specific authority to do so
- Duty of Diligence. Directors ultimately hold full non-delegable responsibility for the Corporation’s actions and well-being. Directors are required to carry out their board responsibilities with careful attentiveness and dedication—attending meetings, actively participating in board deliberations, seeking outside counsel and guidance as appropriate; and ensuring that all state and federal taxes, registrations, returns, and other financial reports required under applicable laws are timely filed.
- Duty of Loyalty. Directors must always act in the best interests of the Society. This applies to not only decisions that involve their own personal or business loyalties, but also those of other key employees, directors, and officers involved in the Society. Directors shall comply at all times with the Conflict of Interest Policy and shall refrain from making non-program loans, gifts, or advances to any person, except as permitted under the Act.
- Duty of Obedience. Directors are required to ensure that the Society’s activities adhere and conform to the charitable, educational, and scientific purposes set forth in the Bylaws and to utilize the assets of the Corporation for the best interest of the Society's beneficiaries. They are to avoid wasting charitable assets. This includes, but is not limited to incurring penalties, fines, and unnecessary taxes.
- Confidentiality. As part of their fiduciary duties owed to the Society, all directors, officers, committee members, and other agents of the Society are expected to maintain appropriate confidentiality of information related to the Society, including donor and supporter lists and related records, fundraising strategies, financial information about the Society, organizational plans, marketing information, expense information, personnel matters, and computer passwords (all whether in electronic or paper format), and to prevent unauthorized disclosure to any outside party, except to the extent such information is otherwise disclosed in accordance with the ordinary course of business to the public or third parties or otherwise is required to be disclosed under applicable law. Such confidentiality is expected to be maintained at all times subsequent to service to the Society. Each director, officer, and key employee shall annually complete a confidentiality agreement.
- Ensure that Council / Committee leaders understand their roles and the relationship between the Councils, the Committees, and the Board
- Provide guidance to the Council/Committee leaders in accomplishing their Board approved goals and objectives
- Participate in all Council / Committee leadership conference calls
- Provide direct communication between the Council/Committee leaders and the Board
- Ensure the required periodic Council/Committee updates and task reports to the Board are adequately prepared and submitted on time
- Provide additional information to the Board regarding Council updates and task reports as requested by the Board
- Communicate with Council/Committee leadership when Board-assigned tasks and responsibilities are not being completed in a timely manner and ask for assistance from Society officers if this communication is not effective in moving things forward
- Regularly provide feedback to the Board, Governance Committee and Executive Committee regarding the effectiveness of the Council / Committee and its leaders
- Proactively inform their Council / Committee leaders of Board actions that will directly or indirectly affect them
- Personal affirmation of agreement to adhere to the Society’s statement of purpose, abide in all respects with the corporate policies set forth in the bylaws and elsewhere, and characterize personal commitment to the mission, purposes, and values of the Society
- Leadership, organizational, and oral/written communication skills
- Commitment to working with a diverse group of individuals to reach consensus
- Ability to work collaboratively with staff, other leaders, and members in a volunteer organization
- Ability to respond to requests and inquiries from staff, other leaders, and members within 72 hours
- Ability to participate in scheduled conference calls and meetings of the Board
- Willingness and ability to enforce Society policies and procedures
- Willingness and ability to motivate and mentor those to whom the Board has delegated responsibility
- At least 2 Board conference calls lasting 2 hours each
- 3 2-day face to face Board meetings
- 2-4 hours per month fulfilling Board liaison responsibilities
- 5-10 hours per month reading and responding to emails, providing input and feedback, reviewing / editing / drafting documents and reports, and preparing for meetings and conference calls
For Individual Board members
- Fellow Officers and Directors
- Executive Director
- Assigned Council or Committee leaders
For the Board as a whole
- Board members enjoy effective working relationships with their fellow Board members, their assigned Council and Committee leaders, and individual staff
- Board members successfully deliver on all of the above responsibilities
- Board members successfully meet the deadlines and expectations for their assigned tasks
- Board members receive positive feedback from the Executive Committee, fellow Board members, the Councils/Committees to which they are liaisons, and staff
- Board members respond favorably to constructive input and course correction, if needed
- Board members feel as if they have made a positive contribution to the Society’s mission, purposes, goals, objectives, and long-term future
- The Board makes decisions that are based on the best interests of the Society
- The Board makes decision that serve to move the Society forward in a consistent manner on the Society’s established goals and objectives
- The Board has effective working relationships with the Executive Committee, Council and Committee Chairs, the management company, and individual staff
- The Board successfully delivers on all of the above Board responsibilities
- The Committee and Council leaders regard the Board as providing effective leadership, decision-making, and guidance to enable them to meet their assigned responsibilities
- The members regard the Board as providing effective leadership of the Society
- The Management Company regards the Board as providing sufficient leadership, decision-making, and oversight of volunteers to enable it to deliver effectively on the Scope of Services
- The volunteers and staff regard the Society’s policies as sufficient and effective in helping them accomplish the work of the Society
- The Society’s long term financial and organizational stability is secure
Members of the 2017-2018 ISHLT Board of Directors convened in April 2017 at the ISHLT Annual Meeting in San Diego, CA.